U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season - Merck.com

Read also:

• GameStop may be a bitcoin play, but its stock is sliding on weaker-than-expected Q1 revenue - MarketWatch
• Tesla’s Retail Army Defies Musk-Trump Spat to Place Record ETF Bet - Bloomberg.com
• For those who were actually old enough to have experienced the 1970s and not for those who were born in the 70s. What were the pros and cons of that era?
• Ad eveniet eaque et magni illum.
• Does red light therapy do anything inside the body, other than just the skin that receives the light? Are there any obscure health benefits?
• Is there a possibility that BTS members will be exposed by "Dispatch" for publicly dating, similar to other K-pop stars who have recently been seen doing so?
• All-time great wrestler Hakuho quits Japan Sumo Association with plans to form global body - AP News
• What percent of "being a good programmer" is due to expertise in the syntax of a language(s)? Could you have mastered syntax and still be a bad programmer; or, conversely, be a great programmer with only a fundamental handle on syntax?
• What is the funniest joke you've been told that you still think about to this day?
• Bad Botox? Six cases of botulism on the South Shore tied to possible Botox injections - The Boston Globe
• Which MBA specialisation is a good option for me? I have a BE computer degree and working in the IT field.
• Nvidia Scores U.K. Artificial Intelligence Infrastructure Deals - Investor's Business Daily
• Intel Stock (NASDAQ:INTC) Blasts Up as Mac Support Dies - TipRanks